Uterine Fibroids Treatment Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 4.96 Billion |
| Market Size (2030) | USD 7.52 Billion |
| Growth Rate (2025 - 2030) | 8.68% CAGR |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Uterine Fibroids Treatment Market Analysis by Mordor Intelligence
The Uterine Fibroids Treatment Market size is estimated at USD 4.96 billion in 2025, and is expected to reach USD 7.52 billion by 2030, at a CAGR of 8.68% during the forecast period (2025-2030).
Demand accelerates as symptomatic fibroids affect up to 80% of women by age 50, with elevated prevalence and earlier onset among Black women[1]Source: JAMA Network Open, “Structural Racism, Health Services Research, and Burden of Uterine Fibroids,” jamanetwork.com. Adoption of minimally invasive and non-invasive options gains pace as patients seek fertility preservation and shorter recovery. Robust reimbursement in high-income nations, paired with faster approvals for oral GnRH antagonists, widens therapeutic choice and expands the uterine fibroids treatment market. Device makers secure growth by integrating artificial intelligence (AI) into procedure planning, while pharmaceutical sponsors extend product life cycles through combination regimens and add-back therapy. Supply-chain resilience around rare-earth embolization particles and HIFU components remains pivotal for uninterrupted procedure volumes.
Key Report Takeways
- By treatment method, surgical procedures led with 43.35% uterine fibroids treatment market share in 2024; non-invasive procedures are forecast to expand at a 9.13% CAGR through 2030.
- By end user, hospitals accounted for a 63.82% share of the uterine fibroids treatment market size in 2024, while ambulatory surgical centers are expected to advance at a 9.67% CAGR through 2030.
- By geography, North America accounted for 42.23% of the uterine fibroids treatment market size in 2024; the Asia-Pacific region is expected to record the fastest regional CAGR of 10.17% from 2024 to 2030.
Global Uterine Fibroids Treatment Market Trends and Insights
Driver Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Prevalence of Symptomatic Fibroids | +1.8% | Global, with higher impact in North America and Europe | Long term (≥ 4 years) |
| Shift Toward Minimally & Non-invasive Procedures | +2.1% | North America & EU, expanding to Asia-Pacific | Medium term (2-4 years) |
| Favorable Reimbursement in High-income Nations | +1.4% | North America, Western Europe, select APAC markets | Short term (≤ 2 years) |
| Launch of Oral GnRH Antagonists | +1.6% | Global, led by developed markets with regulatory approval | Medium term (2-4 years) |
| AI-enabled Imaging & Robotics Adoption | +0.9% | North America, Europe, Japan, South Korea | Medium term (2-4 years) |
| Biomarker-driven Precision Medicine | +0.7% | North America & EU, with spill-over to APAC core markets | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Rising Prevalence of Symptomatic Fibroids
Clinical studies confirm that Black women experience three-fold higher fibroid prevalence and earlier onset than other groups, driving concentrated demand in health systems serving diverse populations[2]Source: Kaiser Permanente Division of Research, “Uterine Fibroid Incidence Differs by Race, Ethnicity,” kaiserpermanente.org. Broader use of high-resolution ultrasound and MRI enables earlier detection, swelling the addressable pool beyond those with severe symptoms. Heightened awareness of fertility impairment linked to untreated fibroids encourages earlier consultation, channeling patients toward uterus-sparing solutions. Together, these factors create durable demand that underpins the uterine fibroids treatment market.
Shift Toward Minimally & Non-Invasive Procedures
Incision-free options such as transcervical radiofrequency ablation treated more than 10,000 patients by August 2024, evidencing rapid adoption. Comparative research shows radiofrequency ablation generated 72.2% live-birth rates without uterine rupture, outperforming conventional myomectomy. Category 1 CPT codes introduced in 2024 removed reimbursement ambiguity and lowered administrative hurdles. High-intensity focused ultrasound records a 9.33% complication rate in overweight patients, less than half that of laparoscopic surgery. Collectively, these clinical and economic benefits tilt physician and patient preference toward uterine-preserving modalities, expanding the uterine fibroids treatment market.
Favorable Reimbursement in High-Income Nations
Medicare pays USD 530 for uterine artery embolization under CPT 37243, ensuring predictable provider revenue streams. Commercial insurers have widened coverage for radiofrequency ablation, trimming out-of-pocket exposure and boosting procedural uptake. Analysis shows treatment patterns vary by insurance type, with broader access linked to comprehensive policies. Such payer alignment accelerates adoption of cost-efficient therapies and fortifies the uterine fibroids treatment market.
Launch of Oral GnRH Antagonists
Relugolix combination therapy lowered the need for surgery in 26% of preoperative patients. Elagolix 150 mg once daily achieved 49.4% response in reducing menstrual blood volume to below 80 mL, double the placebo rate. Add-back options such as Ryeqo mitigate bone-density loss and enable long-term dosing. Oral dosing eliminates injection-site reactions and simplifies adherence, broadening appeal among patients reluctant to undergo invasive treatment. These advantages reinforce growth across the uterine fibroids treatment industry.
Restraint Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Cost of Advanced Devices & Procedures | -1.2% | Global, with higher impact in emerging markets | Medium term (2-4 years) |
| Shortage of Skilled IR Specialists in Emerging Markets | -0.9% | Asia-Pacific, Latin America, Middle East & Africa | Long term (≥ 4 years) |
| Rare-earth Supply Risk for Embolization/HIFU parts | -0.6% | Global, with concentration risk in China-dependent supply chains | Short term (≤ 2 years) |
| Limited Long-term Fertility Data for New Ablation Tech | -0.4% | Global, with regulatory focus in North America & EU | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
High Cost of Advanced Devices & Procedures
Developing and commercializing next-generation fibroid technologies carries significant capital needs; Hologic’s USD 350 million purchase of Gynesonics underscores these investment levels. Limited local manufacturing in emerging economies inflates import costs, placing premium procedures out of reach for uninsured patients. Pandemic-era device shortages highlighted how supply shocks amplify price pressures, especially for rural facilities. Even in high-income markets, out-of-pocket patient costs can exceed USD 25,000 across a treatment journey, prompting delayed care and limiting the uterine fibroids treatment market.
Shortage of Skilled IR Specialists in Emerging Markets
Uterine artery embolization and MR-guided focused ultrasound require experienced operators, yet specialist density remains low outside major urban hospitals. Training programs struggle to keep pace with demand, elongating patient wait times and constraining procedure volumes. The gap is most acute in secondary cities where equipment investment proceeds faster than workforce development. Professional societies promote virtual learning and fellowship exchanges, but tangible capacity gains will take years. Until then, insufficient expertise dampens the growth trajectory of the uterine fibroids treatment market.
Segment Analysis
By Treatment Method: Patient Demand Propels Non-Invasive Innovation
Surgical procedures accounted for 43.35% of the uterine fibroids treatment market share in 2024, reflecting their entrenched clinical role. However, non-invasive options are forecast to grow at a 9.13% CAGR, adding USD 1.4 billion to the uterine fibroids treatment market size by 2030. Long-term follow-up of MR-guided focused ultrasound reveals a 33.1% re-intervention rate over seven years, with women over 44 years of age requiring fewer repeat procedures. Radiofrequency ablation expands indications for overweight patients, meeting an unmet need with lower complication risk.
Pharmacological therapy advances complement device growth. Oral GnRH antagonists provide durable, reversible symptom relief, allowing patients to postpone or avoid surgery. Reimbursement clarity boosts minimally invasive volumes; the Category 1 CPT designation for transcervical ablation is a notable catalyst for this increase. AI planning software accelerates the MR-gFUS workflow, with autonomous agents achieving very high levels of expert acceptance. Collectively, these clinical, economic, and technological elements reinforce momentum toward minimally invasive and non-invasive care, reshaping the uterine fibroids treatment market.
Note: Segment shares of all individual segments available upon report purchase
By End User: Outpatient Migration Strengthens ASC Expansion
Hospitals retained a 63.82% share of the uterine fibroids treatment market size in 2024, benefiting from comprehensive service portfolios and established referral networks. Yet ambulatory surgical centers (ASCs) are projected to post the fastest 9.67% CAGR, capturing patient demand for same-day care and transparent pricing. Medicare reimbursement parity for specific procedures narrows the financial gap, improving ASC economics. Purpose-built women’s health ASCs optimize throughput for radiofrequency ablation and hysteroscopic myomectomy, elevating patient satisfaction metrics.
Hospital systems counter competitive pressure by launching hybrid outpatient centers integrated within broader health networks. These sites offer advanced imaging and critical-care backup while preserving the convenience of non-overnight stays. Specialty gynecology clinics leverage direct-pay models to sidestep insurance delays but face capital hurdles for imaging and ablation equipment. Overall, diversified settings tailor access and affordability, collectively broadening the uterine fibroids treatment market.
Geography Analysis
North America accounted for 42.23% uterine fibroids treatment market share in 2024, underpinned by consistent reimbursement, high diagnostic awareness, and proximity to device innovators. FDA breakthrough device pathways[3]US FDA, "Breakthrough Devices Program," fda.gov expedite commercialization cycles, enabling rapid clinical adoption. Medicare’s fixed payment for uterine artery embolization secures predictable margins, while commercial insurers expand coverage for transcervical and MR-guided techniques. Nonetheless, procedure availability varies, as rural hospitals struggle to maintain interventional radiology staff, prompting regional disparities that temper overall growth.
Asia-Pacific is projected to record the highest 10.17% CAGR through 2030, propelled by healthcare infrastructure upgrades and rising disposable income. China’s status as a leading medical-device manufacturing hub lowers procurement costs and accelerates domestic adoption. Japan and South Korea lead in MR-guided focused ultrasound deployment, reflecting mature imaging capabilities and aging demographics. India’s large addressable population positions it as a future volume driver, contingent on specialist training and public-private investment in women’s health.
Europe demonstrates steady expansion, supported by cohesive regulatory frameworks and widespread insurance coverage. Harmonized clinical guidelines facilitate cross-border referral for complex cases, while rigorous evidence standards ensure consistent quality across treatment centers. Recent reimbursement approvals for oral GnRH antagonists[4]Marta Barretta, "The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications," Expert Opinion on Drug Metabolism & Toxicology, pubmed.ncbi.nlm.nih.gov improve medical-therapy utilization patterns, offering alternatives to surgery for symptomatic women. Regional growth, however, remains sensitive to national budget constraints and the pace of workforce development.
Competitive Landscape
The uterine fibroids treatment market remains moderately fragmented, with device manufacturers and pharmaceutical companies pursuing complementary strategies. AbbVie and Pfizer focus on medical management, extending lifecycle value through add-back therapy co-formulations. Device leaders, such as Hologic and Boston Scientific, emphasize platform breadth by integrating imaging, energy delivery, and disposable consumables into cohesive ecosystems. Hologic’s USD 350 million acquisition of Gynesonics broadens its reach in incision-free solutions, illustrating targeted consolidation to accelerate share capture.
Emerging players are innovating around artificial intelligence and precision diagnostics to automate treatment planning and personalize patient selection. White-space opportunities include biomarker panels that predict symptom severity and recurrence risk, potentially reducing the 33.1% long-term re-intervention rate observed after MR-guided focused ultrasound. Pricing pressure intensifies as patent cliffs invite generic competition for earlier GnRH agonists, prompting incumbents to shift toward value-based contracting. Strategic differentiation is increasingly centered on a seamless patient experience, with single-visit diagnostics and same-day ablation emerging as key competitive must-haves across the uterine fibroids treatment industry.
Uterine Fibroids Treatment Industry Leaders
-
Gynesonics
-
Medtronic
-
INSIGHTEC
-
Myovant Sciences GmbH
-
Boston Scientific Corporation
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- January 2025: Hologic completed its USD 350 million acquisition of Gynesonics, adding the Sonata transcervical ablation platform to its minimally invasive portfolio
- January 2023: Organon invested in Claria Medical to advance minimally invasive hysterectomy devices targeting complex fibroid cases
Global Uterine Fibroids Treatment Market Report Scope
As per the scope of this report, uterine fibroids, also known as uterine myomas or leiomyomas, are non-cancerous tumors that develop in the muscular wall of the uterus. They can vary in size and number. Symptoms include heavy menstrual bleeding (HMB), anemia, abdominal pressure and pain, bloating, increased urinary frequency, and reproductive dysfunction.
The uterine fibroids treatment market is segmented by type, treatment, end user, and geography. The type segment is further segmented into subserosal fibroids, intramural fibroids, submucosal fibroids, pedunculated fibroids, and other types. Other types include cervical fibroids. The treatment segment is further divided into drugs and surgical techniques. The drugs sub-segment is further divided into progesterone, levonorgestrel, and other drugs. Other drugs include mefenamic acid and raloxifene. The surgical techniques are further divided into hysterectomy, myomectomy, myolysis, and other surgical techniques. Other surgical techniques include uterine artery embolization (UAE) and radiofrequency ablation (RFA). The end user segment is further bifurcated into hospitals, specialty clinics, and other end users. Other end-user segments include outpatient centers, home healthcare services, and telemedicine platforms. The geography segment is further segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD) for the above segments.
| Pharmacological Therapy | Hormonal (GnRH antagonists, SPRMs, COCs) |
| Non-hormonal (NSAIDs, Tranexamic Acid) | |
| Surgical Procedures | Hysterectomy |
| Myomectomy (Hysteroscopic • Laparoscopic • Open) | |
| Minimally-Invasive Procedures | Uterine Artery Embolization |
| Radiofrequency Ablation (e.g., Acessa) | |
| Non-Invasive Procedures | MR-guided HIFU |
| Transcervical Fibroid Ablation (Sonata) |
| Hospitals |
| Ambulatory Surgical Centers |
| Specialty Gynecology Clinics |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| India | |
| Japan | |
| South Korea | |
| Australia | |
| Rest of Asia-Pacific | |
| South America | Brazil |
| Argentina | |
| Rest of South America | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa |
| By Treatment Method | Pharmacological Therapy | Hormonal (GnRH antagonists, SPRMs, COCs) |
| Non-hormonal (NSAIDs, Tranexamic Acid) | ||
| Surgical Procedures | Hysterectomy | |
| Myomectomy (Hysteroscopic • Laparoscopic • Open) | ||
| Minimally-Invasive Procedures | Uterine Artery Embolization | |
| Radiofrequency Ablation (e.g., Acessa) | ||
| Non-Invasive Procedures | MR-guided HIFU | |
| Transcervical Fibroid Ablation (Sonata) | ||
| By End User | Hospitals | |
| Ambulatory Surgical Centers | ||
| Specialty Gynecology Clinics | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| India | ||
| Japan | ||
| South Korea | ||
| Australia | ||
| Rest of Asia-Pacific | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
Key Questions Answered in the Report
What is the current global revenue for uterine fibroids treatment and how fast is it growing?
Spending stands at USD 4.96 billion in 2025 and is projected to reach USD 8.70 billion by 2030, reflecting an 8.7% CAGR.
Which therapy type is expanding the quickest?
Non-invasive procedures are forecast to post a 9.13% CAGR through 2030, outpacing all other options as patients seek fertility-preserving, low-recovery solutions.
How are ambulatory surgical centers changing the revenue landscape?
ASC procedure volumes are projected to rise at a 9.67% CAGR thanks to reimbursement parity and patient demand for same-day care, diverting share from inpatient hospitals.
Which geographic region shows the strongest growth outlook through 2030?
Asia-Pacific is set to record the fastest 10.17% CAGR, driven by expanding healthcare infrastructure, rising disposable income, and broader awareness of womens health.
What strategic moves have leading device firms made recently?
Hologic's USD 350 million acquisition of Gynesonics and Meditrina's 510(k) clearance for its Gen 2 RF hysteroscopy system underscore ongoing investment in minimally invasive platforms.
How are oral GnRH antagonists affecting revenue streams?
New approvals for relugolix and linzagolix add durable, reimbursable medical options that reduce surgical demand and broaden the addressable patient base, lifting overall spend.
Page last updated on:
